NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded shares of Sequenom to Neutral, saying that its fight to stay ahead of competitors in the non-invasive fetal chromosome abnormalities testing space may result in greater costs to the company, while its ability to get reimbursement remains uncertain.

The investment bank previously had an Overweight rating on the San Diego-based firm. Piper Jaffray also lowered the price target on Sequenom's shares to $5 from $6.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.